Table 1. Clinical and molecular features of the patients used for the analysis of EPZ005687 in primary patient CD138 selected cells.
| Patient number |
Clinical features |
Molecular features |
|||||
|---|---|---|---|---|---|---|---|
| Age at the time of relapse (years) | No. of prior therapies | Time from first diagnosis (months) |
Previously exposed to: |
Translocation group/HRD | Copy number changes associated with risk | ||
| IMiD | PI | ||||||
| 1 | 57 | 2 | 36 | Y | Y | None | 17p− |
| 2 | 56 | 1 | 27 | Y | Y | t(11;14) | None |
| 3 | 69 | 6 | 109 | Y | Y | t(4;14) FGFR3- | 1p−, 1q amp |
| 4 | 50 | 4 | 33 | Y | Y | t(4;14) FGFR3+ | 1q+ |
| 5 | 66 | 2 | 40 | Y | Y | None | 1q+ |
| 6 | 85 | 1 | 46 | Y | N | HRD | 1q+, 17p− |
| Median | 61.5 | 2 | 38 | ||||
Abbreviations: HRD, hyperdiploid; IMiD, immunomodulatory drug; N, no; PI, proteasome inhibitor; Y, yes.